
    
      The purpose of the study is to determine safety and efficacy of treatment if mixed (cellular
      and antibody) mediated acute rejection with addition of B-cell depleting therapy to
      Thymoglobulin in kidney and simultaneous kidney pancreas allograft recipients.
    
  